Kavita Mariwalla, MD
MOHS-Micrographic Surgery · West Islip, NYNPI 1962674184
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $165,177 of the $221,302 with a category attached, or 74.6%. 33 manufacturers reported payments, led by AbbVie at 40.5% of the total. Reporting peaked in 2019 at $63,275 and has fallen 61.1% since, to $24,605 in 2025. Among mohs-micrographic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $974.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$90K
- Merz North America, Inc.$63K
- Galderma Laboratories, L.p.$25K
- Sandoz$16K
- Dermira, Inc.$10K
- Pfizer$7K
- plus $10K from 27 others
Across 45 payments — averaging $13,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$520K
- Merz North America, Inc.$96K
What the payments were for
- Consulting fees$165,17775%
- Speaking & faculty fees$20,1229%
- Travel & lodging$26,59312%
- Food & beverage$8,6974%
- Education$7130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $89,721 |
| Merz North America, Inc. | 34 | $63,189 |
| Galderma Laboratories, L.p. | 51 | $24,584 |
| Sandoz | 2 | $16,000 |
| Dermira, Inc. | 8 | $10,150 |
| Pfizer | 6 | $7,263 |
| Galderma Research & Development, LLC | 1 | $4,180 |
| Sanofi | 2 | $1,843 |
| Regeneron Healthcare Solutions, Inc. | 3 | $1,352 |
| Arcutis Biotherapeutics, Inc. | 10 | $681 |
| Johnson & Johnson | 12 | $645 |
| Aclaris Therapeutics, Inc. | 1 | $500 |
| Sanofi-aventis U.S. LLC | 3 | $322 |
| Sun Pharmaceutical Industries Inc. | 13 | $234 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $71 |
| Medimetriks Pharmaceuticals, Inc. | 3 | $70 |
| Novartis | 4 | $49 |
| Amgen | 2 | $46 |
| Lilly USA, LLC | 2 | $41 |
| Dermavant Sciences, Inc. | 2 | $33 |
| Encore Dermatology Inc. | 1 | $24 |
| Boston Scientific | 1 | $24 |
| EPI Health, LLC | 1 | $22 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
| Promius Pharma LLC | 1 | $19 |
| Almirall LLC | 1 | $19 |
| Biofrontera Inc. | 1 | $19 |
| Journey Medical Corporation | 1 | $18 |
| Genentech USA, Inc. | 1 | $14 |
| Strata Skin Sciences, Inc. | 1 | $14 |
| LEO Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,302 in reported general payments places this provider in the 95th percentile of 75 mohs-micrographic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 12 | $76,991 |
| Dupixent SyringeDupilumab | 12 | $56,177 |
| OpzeluraRuxolitinib Phosphate | 14 | $33,056 |
| VtamaTapinarof | 16 | $21,610 |
| Tacrolimus | 73 | $12,388 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 16 | $11,587 |
| Ketoconazole | 317 | $6,579 |
| CiclopiroxCiclopirox Olamine | 164 | $4,334 |
| Pimecrolimus | 12 | $4,078 |
| Ivermectin | 15 | $3,218 |
| Fluorouracil | 40 | $2,765 |
| Azelaic Acid | 17 | $2,183 |
| Imiquimod | 26 | $2,172 |
| Clindamycin Phosphate | 68 | $2,059 |
| Metronidazole | 51 | $1,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $46 | $76,99112 claims |
| Dermavant Sciences, Inc.Vtama | $33 | $21,61016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 mohs-micrographic surgery providers in New York.
Other mohs-micrographic surgery in West Islip
- Daniel SiegelSmithtown$450K
- Sherrif IbrahimVictor$412K
- Ellen MarmurNew York$186K
- Kenneth MarkSouthampton$91K
- Michael TassavorNew York$55K
- Jane YooNew York$42K
- Hamza BhattiNew York$40K
- Desiree RatnerNew York$32K
- Eyal LevitBrooklyn$22K
- Omar Torres LozadaNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.